Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027308 | 1.00 | DPP4 (0.59) | DPP4DPP7DPP8PIN1KCNH2 | |
| SCHEMBL29478415 | 1.00 | DPP4 (0.59) | DPP4DPP7DPP8PIN1KCNH2 | |
| SCHEMBL29478387 | 1.00 | DPP4 (0.59) | DPP4DPP7DPP8PIN1KCNH2 | |
| SCHEMBL2027312 | 1.00 | DPP4 (0.59) | DPP4DPP7DPP8PIN1KCNH2 | |
| SCHEMBL288344 | 0.81 | DPP4 (0.54) | DPP4DPP7DPP8ANPEPENPEP | |
| SCHEMBL2030773 | 0.81 | DPP4 (0.54) | DPP4DPP7DPP8ANPEPENPEP | |
| SCHEMBL2028678 | 0.81 | DPP4 (0.54) | DPP4DPP7DPP8ANPEPENPEP | |
| SCHEMBL44052 | 0.79 | SLC7A5 (0.62) | KDM4EUSP2EGFRLCKFYN | |
| SCHEMBL1613644 | 0.79 | SLC7A5 (0.62) | KDM4EUSP2EGFRLCKFYN | |
| SCHEMBL18511382 | 0.79 | SLC7A5 (0.62) | KDM4EUSP2EGFRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | DPP4 1217/4885DPP7 481/4885DPP8 994/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | DPP4 1374/4885DPP7 453/4885DPP8 959/4885 |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | RNGTT, SPOUT1, NPEPPS | DPP4 2157/4885DPP7 772/4885DPP8 726/4885 |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | DPP4 93/4885DPP7 127/4885DPP8 143/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | DPP4 2835/4885DPP7 1615/4885DPP8 1277/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | DPP4 265/4885DPP7 232/4885DPP8 396/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | DPP4 1357/4885DPP7 865/4885DPP8 827/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | DPP4 677/4885DPP7 694/4885DPP8 664/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | DPP4 128/4885DPP7 50/4885DPP8 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.